DOCSLIB.ORG

Genetic Contribution to Chronic Tinnitus in Patients with Meniere's

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genetic Contribution to Chronic Tinnitus in Patients with Meniere's Doctoral program in Biomedicine (B11.56.1) Genetic Contribution to Chronic Tinnitus in Patients with Meniere’s Disease and Tinnitus Extreme Phenotype (MD-TEP) Contribución genética al acúfeno crónico en pacientes de enfermedad de Meniere con fenotipo extremo de acúfeno (MD-TEP) International PhD Thesis Tesis Doctoral con Mencion International Sana Amanat Ali May, 2021 Granada Editor: Universidad de Granada. Tesis Doctorales Autor: Sana Amanat Ali ISBN: 978-84-1306-904-3 URI: http://hdl.handle.net/10481/69097 2 Acknowledgements It was not possible to carry out this thesis without the help and collaboration of many people. Thanks to my family especially my parents and sisters who supported my decision of moving abroad to pursue my PhD. Thanks for your constant support, I will never forget. Off course, I can't. This decision seems to have paid off now. Decisions and coincidences that changed my life, Undergraduation in Computer science, Master in Computer science and then Doctorate in Biomedicine as a Bioinformatician. I would like to take this opportunity to thanks Antonio for yout constant support, my supervisor. Thank you for trusting me and giving me the opportunity to be a part of this prestigious group. I was not very clear when I started but you have made sure that it was as straight as possible. Having little or no knowledge of exome sequencing, you taught me very well from basics to advance topics. It is time to thank all the colleagues with whom I have been lucky enough to work in GENyO. I would like to thanks Teresa Requena and Lidia Frejo for your kind support; though we spent very few months together but I will never forget. I am grateful to Álvaro Gallego for your help whenever i have questions and doubts. You helped me a lot to build my understanding about biological interpretation of data. I would like to thanks Pablo for his constant help. I would like to thanks Olga, you have been a great support for me in all administrative tasks related to my contract, even before my arrival. Thanks for churros con chocolate and funny moments we shared. Thank you very much Marisa, for making my stay exciting and cheerful. Thanks for the good and quality time we spent. I still remember few of Portuguese words, thanks for it. Thank you Estrella for the good time we spent, I will remember your name as Star. Alba, thanks for your help whenever I needed, you were always willing to help me. I would like to thanks all Master students for the discussion we had. It is time to say a big thanks to everyone from ESIT. My ESIT colleagues and friends have been a great support for me throughout this journey. Thanks for the amazing trainings, workshops and courses. It was the best time. Thanks to Christopher for organizing my online stay at Karolinska Institute, and arranging amazing activities during this stay. I would like to extend my thanks to Meniere society, UK for hosting my stay. Many thanks to Juanma, Patricia and all clinicians for your participation in this study. Thanks for providing us the samples and clinical data to made this study possible. I would like to thanks Patrick and Joseph for your amazing contribution in this study. I would like to say thanks to all the patients and their families for their support. I hope that together we can find the solution one day. I don't want to forget anyone, Thanks to all those who are in my heart and silently supporting me. Thank to everyone even if I haven't mentioned the name. Thanks to Ammi, Abu, Nida, Farah, Ghazala, Madeha, Farzana, Saeed, Moid, Zamna, Rehana, Mubarak, Ammar and Tayyaba. Thank a lot. 5 6 Contents Funding ................................................................................................................................................................ 9 Resumen ............................................................................................................................................................ 10 Abstract ............................................................................................................................................................. 11 List of abbreviations .......................................................................................................................................... 13 1. Introduction ............................................................................................................................................... 14 1.1. Tinnitus: a complex trait .................................................................................................................... 14 1.2. Inner ear and the peripheral auditory system ..................................................................................... 15 1.2.1. Anatomy of cochlea and its function ......................................................................................... 16 1.2.2. Anatomy of vestibular labyrinth and its function ...................................................................... 17 1.2.3. The auditory central nervous system and tinnitus mechanism .................................................. 18 1.3. Meniere disease ................................................................................................................................. 20 1.3.1. Vertigo ....................................................................................................................................... 20 1.3.2. Sensorineural hearing loss ......................................................................................................... 21 1.3.3. Tinnitus ...................................................................................................................................... 21 1.3.4. Aural fullness ............................................................................................................................. 21 1.4. Extreme phenotype ............................................................................................................................ 21 1.5. Diagnosis and classification .............................................................................................................. 24 1.6. Genetic variants ................................................................................................................................. 25 1.7. Pathogenicity of rare variants ............................................................................................................ 27 1.8. Heritability and genetics contribution to tinnitus .............................................................................. 29 2. Hypothesis ................................................................................................................................................. 31 3. Objectives .................................................................................................................................................. 32 3.1. Main objective ................................................................................................................................... 32 3.2. Specific objectives ............................................................................................................................. 32 4. Methods ..................................................................................................................................................... 33 4.1. Systematic review of extreme phenotype strategies .......................................................................... 33 4.1.1. Search strategy ........................................................................................................................... 33 4.1.2. Research Question and Selection Criteria ................................................................................. 33 4.1.3. Quality assessment of selected studies ...................................................................................... 34 4.1.4. Data Extraction and Synthesis ................................................................................................... 35 4.2. Subjects and definition of phenotype ................................................................................................ 35 4.3. Whole-exome sequencing ................................................................................................................. 36 4.4. Bioinformatics analysis ..................................................................................................................... 36 7 4.5. Gene Ontology and gene-set enrichment analysis ............................................................................. 39 4.6. Gene expression analysis using the Allen Brain Atlas ...................................................................... 39 4.7. Statistical analysis ............................................................................................................................. 40 5. Results ....................................................................................................................................................... 41 5.1. Selection and Characteristics of EP Studies ...................................................................................... 41 5.2. Synthesized Findings of EP Studies .................................................................................................. 42 5.3. Rare missense variants in synaptic genes associated with tinnitus extreme phenotype in MD patients. .........................................................................................................................................................
Load more

Recommended publications
  • Whole-Genome Microarray Detects Deletions and Loss of Heterozygosity of Chromosome 3 Occurring Exclusively in Metastasizing Uveal Melanoma
    Anatomy and Pathology Whole-Genome Microarray Detects Deletions and Loss of Heterozygosity of Chromosome 3 Occurring Exclusively in Metastasizing Uveal Melanoma Sarah L. Lake,1 Sarah E. Coupland,1 Azzam F. G. Taktak,2 and Bertil E. Damato3 PURPOSE. To detect deletions and loss of heterozygosity of disease is fatal in 92% of patients within 2 years of diagnosis. chromosome 3 in a rare subset of fatal, disomy 3 uveal mela- Clinical and histopathologic risk factors for UM metastasis noma (UM), undetectable by fluorescence in situ hybridization include large basal tumor diameter (LBD), ciliary body involve- (FISH). ment, epithelioid cytomorphology, extracellular matrix peri- ϩ ETHODS odic acid-Schiff-positive (PAS ) loops, and high mitotic M . Multiplex ligation-dependent probe amplification 3,4 5 (MLPA) with the P027 UM assay was performed on formalin- count. Prescher et al. showed that a nonrandom genetic fixed, paraffin-embedded (FFPE) whole tumor sections from 19 change, monosomy 3, correlates strongly with metastatic death, and the correlation has since been confirmed by several disomy 3 metastasizing UMs. Whole-genome microarray analy- 3,6–10 ses using a single-nucleotide polymorphism microarray (aSNP) groups. Consequently, fluorescence in situ hybridization were performed on frozen tissue samples from four fatal dis- (FISH) detection of chromosome 3 using a centromeric probe omy 3 metastasizing UMs and three disomy 3 tumors with Ͼ5 became routine practice for UM prognostication; however, 5% years’ metastasis-free survival. to 20% of disomy 3 UM patients unexpectedly develop metas- tases.11 Attempts have therefore been made to identify the RESULTS. Two metastasizing UMs that had been classified as minimal region(s) of deletion on chromosome 3.12–15 Despite disomy 3 by FISH analysis of a small tumor sample were found these studies, little progress has been made in defining the key on MLPA analysis to show monosomy 3.
    [Show full text]
  • Novel Protein RGPR-P117
    a ular nd G ec en l e o t i M c f M o l e Journal of Molecular and Genetic d a i Yamaguchi, J Mol Genet Med 2013, 7:3 n c r i n u e o J Medicine DOI: 10.4172/1747-0862.1000072 ISSN: 1747-0862 MiniResearch Review Article OpenOpen Access Access Novel Protein RGPR-p117: New Aspects in Cell Regulation Masayoshi Yamaguchi* Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, USA Abstract RGPR-p117 was initially discovered as novel protein which binds to the nuclear factor I (NF1)-like motif TTGGC(N)6CC in the regucalcin gene promoter region (RGPR). RGPR-p117 is localized to the nucleus with stimulation of protein kinase C-related signaling process. Overexpression of RGPR-p117 has been shown to enhance regucalcin mRNA expression in the cloned normal rat kidney proximal tubular epithelial NRK52E cells in vitro. This process is mediated through phosphorylated RGPR-p117. Overexpression of RGPR-p117 was found to suppress apoptotic cell death induced after stimulation with various signaling factors in NRK52E cells, while it did not have an effect on cell proliferation. Moreover, RGPR-p117 was found to localize in the plasma membranes, mitochondria and microsomes, suggesting an involvement in the regulation of function of these organelles. After that, RGPR-p117 was renamed as Sec16B that is involved in the endoplasmic reticulum export. However, this is not suitable name with many findings of the role of RGPR-p117 in cell regulation. RGPR-p117 may play an essential role as transcription factor, and the elucidation of other roles in cell regulation will be expected.
    [Show full text]
  • A Novel Resveratrol Analog: Its Cell Cycle Inhibitory, Pro-Apoptotic and Anti-Inflammatory Activities on Human Tumor Cells
    A NOVEL RESVERATROL ANALOG : ITS CELL CYCLE INHIBITORY, PRO-APOPTOTIC AND ANTI-INFLAMMATORY ACTIVITIES ON HUMAN TUMOR CELLS A dissertation submitted to Kent State University in partial fulfillment of the requirements for the degree of Doctor of Philosophy by Boren Lin May 2006 Dissertation written by Boren Lin B.S., Tunghai University, 1996 M.S., Kent State University, 2003 Ph. D., Kent State University, 2006 Approved by Dr. Chun-che Tsai , Chair, Doctoral Dissertation Committee Dr. Bryan R. G. Williams , Co-chair, Doctoral Dissertation Committee Dr. Johnnie W. Baker , Members, Doctoral Dissertation Committee Dr. James L. Blank , Dr. Bansidhar Datta , Dr. Gail C. Fraizer , Accepted by Dr. Robert V. Dorman , Director, School of Biomedical Sciences Dr. John R. Stalvey , Dean, College of Arts and Sciences ii TABLE OF CONTENTS LIST OF FIGURES……………………………………………………………….………v LIST OF TABLES……………………………………………………………………….vii ACKNOWLEDGEMENTS….………………………………………………………….viii I INTRODUCTION….………………………………………………….1 Background and Significance……………………………………………………..1 Specific Aims………………………………………………………………………12 II MATERIALS AND METHODS.…………………………………………….16 Cell Culture and Compounds…….……………….…………………………….….16 MTT Cell Viability Assay………………………………………………………….16 Trypan Blue Exclusive Assay……………………………………………………...18 Flow Cytometry for Cell Cycle Analysis……………..……………....……………19 DNA Fragmentation Assay……………………………………………...…………23 Caspase-3 Activity Assay………………………………...……….….…….………24 Annexin V-FITC Staining Assay…………………………………..…...….………28 NF-kappa B p65 Activity Assay……………………………………..………….…29
    [Show full text]
  • Supplementary Materials
    Supplementary materials Supplementary Table S1: MGNC compound library Ingredien Molecule Caco- Mol ID MW AlogP OB (%) BBB DL FASA- HL t Name Name 2 shengdi MOL012254 campesterol 400.8 7.63 37.58 1.34 0.98 0.7 0.21 20.2 shengdi MOL000519 coniferin 314.4 3.16 31.11 0.42 -0.2 0.3 0.27 74.6 beta- shengdi MOL000359 414.8 8.08 36.91 1.32 0.99 0.8 0.23 20.2 sitosterol pachymic shengdi MOL000289 528.9 6.54 33.63 0.1 -0.6 0.8 0 9.27 acid Poricoic acid shengdi MOL000291 484.7 5.64 30.52 -0.08 -0.9 0.8 0 8.67 B Chrysanthem shengdi MOL004492 585 8.24 38.72 0.51 -1 0.6 0.3 17.5 axanthin 20- shengdi MOL011455 Hexadecano 418.6 1.91 32.7 -0.24 -0.4 0.7 0.29 104 ylingenol huanglian MOL001454 berberine 336.4 3.45 36.86 1.24 0.57 0.8 0.19 6.57 huanglian MOL013352 Obacunone 454.6 2.68 43.29 0.01 -0.4 0.8 0.31 -13 huanglian MOL002894 berberrubine 322.4 3.2 35.74 1.07 0.17 0.7 0.24 6.46 huanglian MOL002897 epiberberine 336.4 3.45 43.09 1.17 0.4 0.8 0.19 6.1 huanglian MOL002903 (R)-Canadine 339.4 3.4 55.37 1.04 0.57 0.8 0.2 6.41 huanglian MOL002904 Berlambine 351.4 2.49 36.68 0.97 0.17 0.8 0.28 7.33 Corchorosid huanglian MOL002907 404.6 1.34 105 -0.91 -1.3 0.8 0.29 6.68 e A_qt Magnogrand huanglian MOL000622 266.4 1.18 63.71 0.02 -0.2 0.2 0.3 3.17 iolide huanglian MOL000762 Palmidin A 510.5 4.52 35.36 -0.38 -1.5 0.7 0.39 33.2 huanglian MOL000785 palmatine 352.4 3.65 64.6 1.33 0.37 0.7 0.13 2.25 huanglian MOL000098 quercetin 302.3 1.5 46.43 0.05 -0.8 0.3 0.38 14.4 huanglian MOL001458 coptisine 320.3 3.25 30.67 1.21 0.32 0.9 0.26 9.33 huanglian MOL002668 Worenine
    [Show full text]
  • Analysis of the Indacaterol-Regulated Transcriptome in Human Airway
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2018/04/13/jpet.118.249292.DC1 1521-0103/366/1/220–236$35.00 https://doi.org/10.1124/jpet.118.249292 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 366:220–236, July 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Analysis of the Indacaterol-Regulated Transcriptome in Human Airway Epithelial Cells Implicates Gene Expression Changes in the s Adverse and Therapeutic Effects of b2-Adrenoceptor Agonists Dong Yan, Omar Hamed, Taruna Joshi,1 Mahmoud M. Mostafa, Kyla C. Jamieson, Radhika Joshi, Robert Newton, and Mark A. Giembycz Departments of Physiology and Pharmacology (D.Y., O.H., T.J., K.C.J., R.J., M.A.G.) and Cell Biology and Anatomy (M.M.M., R.N.), Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada Received March 22, 2018; accepted April 11, 2018 Downloaded from ABSTRACT The contribution of gene expression changes to the adverse and activity, and positive regulation of neutrophil chemotaxis. The therapeutic effects of b2-adrenoceptor agonists in asthma was general enriched GO term extracellular space was also associ- investigated using human airway epithelial cells as a therapeu- ated with indacaterol-induced genes, and many of those, in- tically relevant target. Operational model-fitting established that cluding CRISPLD2, DMBT1, GAS1, and SOCS3, have putative jpet.aspetjournals.org the long-acting b2-adrenoceptor agonists (LABA) indacaterol, anti-inflammatory, antibacterial, and/or antiviral activity. Numer- salmeterol, formoterol, and picumeterol were full agonists on ous indacaterol-regulated genes were also induced or repressed BEAS-2B cells transfected with a cAMP-response element in BEAS-2B cells and human primary bronchial epithelial cells by reporter but differed in efficacy (indacaterol $ formoterol .
    [Show full text]
  • SETMAR Antibody
    Product Datasheet SETMAR Antibody Catalog No: #43086 Orders: [email protected] Description Support: [email protected] Product Name SETMAR Antibody Host Species Rabbit Clonality Polyclonal Purification Antigen affinity purification. Applications WB IHC Species Reactivity Hu Specificity The antibody detects endogenous levels of total SETMAR protein. Immunogen Type protein Immunogen Description Fusion protein of human SETMAR Target Name SETMAR Other Names Mar1; HsMar1; METNASE Accession No. Swiss-Prot#: Q53H47Gene ID: 6419 Calculated MW 78kd Concentration 1mg/ml Formulation Rabbit IgG in pH7.4 PBS, 0.05% NaN3, 40% Glycerol. Storage Store at -20°C Application Details Western blotting: 1:200-1:1000 Immunohistochemistry: 1:20-1:100 Images Gel: 6%SDS-PAGE Lysate: 40 µg Lane: Jurkat cell Primary antibody: 1/400 dilution Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution Exposure time: 30 seconds Address: 8400 Baltimore Ave., Suite 302, College Park, MD 20740, USA http://www.sabbiotech.com 1 Immunohistochemical analysis of paraffin-embedded Human liver cancer tissue using #43086 at dilution 1/20. Immunohistochemical analysis of paraffin-embedded Human thyroid cancer tissue using #43086 at dilution 1/20. Background This gene encodes a fusion protein that contains an N-terminal histone-lysine N-methyltransferase domain and a C-terminal mariner transposase domain. The encoded protein binds DNA and functions in DNA repair activities including non-homologous end joining and double strand break repair. The SET domain portion of this protein specifically methylates histone H3 lysines 4 and 36. This gene exists as a fusion gene only in anthropoid primates, other organisms lack mariner transposase domain. Note: This product is for in vitro research use only and is not intended for use in humans or animals.
    [Show full text]
  • Mouse Setmar Conditional Knockout Project (CRISPR/Cas9)
    https://www.alphaknockout.com Mouse Setmar Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Setmar conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Setmar gene (NCBI Reference Sequence: NM_178391 ; Ensembl: ENSMUSG00000034639 ) is located on Mouse chromosome 6. 2 exons are identified, with the ATG start codon in exon 1 and the TAG stop codon in exon 2 (Transcript: ENSMUST00000049246). Exon 2 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Setmar gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP23-93D20 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Exon 2 covers 82.85% of the coding region. Start codon is in exon 1, and stop codon is in exon 2. The size of intron 1 for 5'-loxP site insertion: 10466 bp. The size of effective cKO region: ~2167 bp. The cKO region does not have any other known gene. Page 1 of 7 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele 5' gRNA region gRNA region 3' 1 2 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Setmar Homology arm cKO region loxP site Page 2 of 7 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats.
    [Show full text]
  • Birth of a Chimeric Primate Gene by Capture of the Transposase Gene
    Birth of a chimeric primate gene by capture of the SEE COMMENTARY transposase gene from a mobile element Richard Cordaux*, Swalpa Udit†, Mark A. Batzer*, and Ce´ dric Feschotte†‡ *Department of Biological Sciences, Biological Computation and Visualization Center, Center for BioModular Multi-Scale Systems, Louisiana State University, 202 Life Sciences Building, Baton Rouge, LA 70803; and †Department of Biology, University of Texas, Arlington, TX 76019 Edited by Susan R. Wessler, University of Georgia, Athens, GA, and approved March 27, 2006 (received for review February 10, 2006) The emergence of new genes and functions is of central impor- SETMAR transcript, which consists of these three exons, is tance to the evolution of species. The contribution of various types predicted to encode a protein of 671 amino acids and is of duplications to genetic innovation has been extensively inves- supported by 48 human cDNA clones from 18 different normal tigated. Less understood is the creation of new genes by recycling and͞or cancerous tissues (Table 1, which is published as sup- of coding material from selfish mobile genetic elements. To inves- porting information on the PNAS web site; refs. 14 and 15). tigate this process, we reconstructed the evolutionary history of These data suggest that the SETMAR protein is broadly ex- SETMAR, a new primate chimeric gene resulting from fusion of a pressed and has an important, yet unknown, function in human. SET histone methyltransferase gene to the transposase gene of a Recently, it was shown that the SET domain of the SETMAR mobile element. We show that the transposase gene was recruited protein exhibits histone methyltransferase activity (15), as do all as part of SETMAR 40–58 million years ago, after the insertion of known SET domains (16, 17).
    [Show full text]
  • Sec16 As an Integrator of Signaling to the Endoplasmic Reticulum
    Sec16 as an integrator of signaling to the endoplasmic reticulum Dissertation submitted for the degree of Doctor of Natural Sciences (Dr. rer. nat.) Presented by Kerstin Tillmann at the Faculty of Sciences Department of Biology University of Konstanz Date of the oral examination: September 11th, 2015 First referee: Prof. Dr. Daniel Legler Second referee: PD Dr. Hesso Farhan Third referee: Prof. Dr. Sebastian Springer Konstanzer Online-Publikations-System (KOPS) URL: http://nbn-resolving.de/urn:nbn:de:bsz:352-0-305723 Table of Contents Summary ........................................................................................ 1 Zusammenfassung ........................................................................ 2 Introduction .................................................................................... 3 The Secretory Pathway ........................................................................................... 4 1 Structure of the Secretory Pathway ..............................................................................4 2 Endoplasmic reticulum ...................................................................................................9 2.1 Protein translocation into the ER ...............................................................................9 2.2 Protein maturation in the ER lumen ....................................................................... 10 2.3 Quality control and ERAD ...................................................................................... 11 3 ER exit sites .................................................................................................................
    [Show full text]
  • 1 the TRAPP Complex Mediates Secretion Arrest Induced by Stress Granule Assembly Francesca Zappa1, Cathal Wilson1, Giusepp
    bioRxiv preprint doi: https://doi.org/10.1101/528380; this version posted February 5, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. The TRAPP complex mediates secretion arrest induced by stress granule assembly Francesca Zappa1, Cathal Wilson1, Giuseppe Di Tullio1, Michele Santoro1, Piero Pucci2, Maria Monti2, Davide D’Amico1, Sandra Pisonero Vaquero1, Rossella De Cegli1, Alessia Romano1, Moin A. Saleem3, Elena Polishchuk1, Mario Failli1, Laura Giaquinto1, Maria Antonietta De Matteis1, 2 1 Telethon Institute of Genetics and Medicine, Pozzuoli (Naples), Italy 2 Federico II University, Naples, Italy 3 Bristol Renal, Bristol Medical School, University of Bristol, UK Correspondence to: [email protected], [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/528380; this version posted February 5, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. The TRAnsport-Protein-Particle (TRAPP) complex controls multiple membrane trafficking steps and is thus strategically positioned to mediate cell adaptation to diverse environmental conditions, including acute stress. We have identified TRAPP as a key component of a branch of the integrated stress response that impinges on the early secretory pathway. TRAPP associates with and drives the recruitment of the COPII coat to stress granules (SGs) leading to vesiculation of the Golgi complex and an arrest of ER export.
    [Show full text]
  • ADHD) Gene Networks in Children of Both African American and European American Ancestry
    G C A T T A C G G C A T genes Article Rare Recurrent Variants in Noncoding Regions Impact Attention-Deficit Hyperactivity Disorder (ADHD) Gene Networks in Children of both African American and European American Ancestry Yichuan Liu 1 , Xiao Chang 1, Hui-Qi Qu 1 , Lifeng Tian 1 , Joseph Glessner 1, Jingchun Qu 1, Dong Li 1, Haijun Qiu 1, Patrick Sleiman 1,2 and Hakon Hakonarson 1,2,3,* 1 Center for Applied Genomics, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA; [email protected] (Y.L.); [email protected] (X.C.); [email protected] (H.-Q.Q.); [email protected] (L.T.); [email protected] (J.G.); [email protected] (J.Q.); [email protected] (D.L.); [email protected] (H.Q.); [email protected] (P.S.) 2 Division of Human Genetics, Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA 3 Department of Human Genetics, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA * Correspondence: [email protected]; Tel.: +1-267-426-0088 Abstract: Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder with poorly understood molecular mechanisms that results in significant impairment in children. In this study, we sought to assess the role of rare recurrent variants in non-European populations and outside of coding regions. We generated whole genome sequence (WGS) data on 875 individuals, Citation: Liu, Y.; Chang, X.; Qu, including 205 ADHD cases and 670 non-ADHD controls. The cases included 116 African Americans H.-Q.; Tian, L.; Glessner, J.; Qu, J.; Li, (AA) and 89 European Americans (EA), and the controls included 408 AA and 262 EA.
    [Show full text]
  • A Guide to Obesity and the Metabolic Syndrome
    A GUIDE TO OBESITY AND THE METABOLIC SYNDROME ORIGINS AND TREAT MENT GEORG E A. BRA Y Louisiana State University, Baton Rouge, USA Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business © 2011 by Taylor and Francis Group, LLC CRC Press Taylor & Francis Group 6000 Broken Sound Parkway NW, Suite 300 Boca Raton, FL 33487-2742 © 2011 by Taylor and Francis Group, LLC CRC Press is an imprint of Taylor & Francis Group, an Informa business No claim to original U.S. Government works Printed in the United States of America on acid-free paper 10 9 8 7 6 5 4 3 2 1 International Standard Book Number: 978-1-4398-1457-4 (Hardback) This book contains information obtained from authentic and highly regarded sources. Reasonable efforts have been made to publish reliable data and information, but the author and publisher cannot assume responsibility for the valid- ity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint. Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or uti- lized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopy- ing, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.
    [Show full text]